©NIJPP
Publications 2025

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY (NIJPP)

Volume 6 Issue 1 Page 141-145, 2025

https://doi.org/10.59298/NIJPP/2025/61141145

The Role of Hormonal Changes in the Development of Benign Prostatic Hyperplasia: A Mini Review

Bwanbale Geoffrey David

Faculty of Pharmacy Kampala International University Uganda

ABSTRACT

Benign prostatic hyperplasia (BPH) is a prevalent condition among aging males, characterized by the nonmalignant enlargement of the prostate gland, which can significantly impact the quality of life through urinary symptoms and complications. The etiology of BPH is multifactorial, with hormonal changes playing a central role in its pathogenesis. This review explores the intricate relationship between hormonal fluctuations, including testosterone, dihydrotestosterone (DHT), estrogen, and prolactin, and the development of BPH. Evidence suggests that androgenic hormones, particularly DHT, drive prostate growth by activating signaling pathways that enhance cell proliferation and inhibit apoptosis. The interplay between estrogen and androgen receptors further modulates prostate tissue remodeling. Additionally, age-related alterations in hormone levels, such as declining testosterone and increasing estrogen-to-androgen ratios, contribute to the pathological changes observed in BPH. This article also discusses the role of systemic hormones like insulin and leptin in prostate stromal-epithelial interactions. Understanding the hormonal underpinnings of BPH provides insights into therapeutic approaches targeting hormonal pathways for disease management and highlights areas for future research.

Keywords: benign prostatic hyperplasia, hormonal changes, dihydrotestosterone, estrogen, androgen receptor, prostate growth

INTRODUCTION

Benign prostatic hyperplasia (BPH) is a prevalent condition in aging men, with its incidence rising steadily with advancing age. It is primarily defined by a non-malignant enlargement of the prostate gland, resulting from the hyperplasia of both stromal and epithelial cells within the transitional zone of the prostate[1–4]. This pathological growth contributes to obstruction of the lower urinary tract, manifesting as lower urinary tract symptoms (LUTS), including increased urinary frequency, urgency, weak stream, nocturia, and incomplete bladder emptying[5, 6]. The etiology of BPH is multifactorial and not entirely understood, but hormonal dysregulation is recognized as a pivotal factor driving the disease. Androgens, particularly dihydrotestosterone (DHT), play a central role by promoting cellular proliferation and reducing apoptosis in the prostate[7, 8]. DHT is synthesized from testosterone via the enzyme 5α-reductase and exerts its effects by binding to androgen receptors in prostate tissues. This androgen-mediated pathway is thought to maintain prostate growth in adulthood but becomes dysregulated with age, contributing to BPH development [9].

Estrogens, another class of hormones, are also implicated in the pathogenesis of BPH. The prostate contains both estrogen receptor alpha (ERα) and beta (ERβ), which mediate the effects of estrogen on cellular growth and differentiation. While ERα is associated with promoting stromal cell proliferation, ERβ appears to counterbalance these effects by inducing apoptosis and anti-inflammatory responses. An imbalance in estrogen receptor signaling, driven by age-related changes in the androgen-to-estrogen ratio, may exacerbate prostatic hyperplasia. Furthermore, metabolic and hormonal alterations associated with aging, such as insulin resistance, hyperinsulinemia, and increased levels of inflammatory cytokines, have been linked to BPH progression. Chronic inflammation within the prostate microenvironment may stimulate cytokine production and oxidative stress, perpetuating a cycle of tissue remodeling and hyperplasia [10, 11].

This review looks into the intricate hormonal mechanisms contributing to BPH pathogenesis, including the roles of androgens, estrogens, and other hormonal mediators. It also explores the interplay between hormonal dysregulation and inflammation in disease progression, providing insights into potential therapeutic targets for managing BPH and its associated LUTS.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

Androgens in Prostate Growth Androgens, particularly testosterone and its potent derivative dihydrotestosterone (DHT), are essential for the development, differentiation, and maintenance of normal prostate function. Testosterone, synthesized in the testes and to a lesser extent in the adrenal glands, serves as a precursor to DHT. Within prostate tissue, the enzyme 5α-reductase converts testosterone to DHT, a more biologically active androgen. DHT exhibits a significantly higher binding affinity for androgen receptors (AR) compared to testosterone[12]. Once bound, the DHT-AR complex undergoes a conformational change, translocates into the nucleus, and binds to androgen response elements (AREs) in the DNA. This binding initiates transcriptional programs that regulate genes involved in cellular proliferation, differentiation, and survival[13]. While systemic testosterone levels decline gradually with age, studies reveal that intraprostatic DHT concentrations are maintained through local mechanisms, such as increased 5α-reductase activity and androgen recycling. This preservation of intraprostatic DHT ensures sustained androgen receptor activation, which may drive pathological processes. In benign prostatic hyperplasia (BPH), for instance, the prolonged androgenic stimulation leads to an increase in stromal and epithelial cell proliferation, resulting in prostate enlargement. Similarly, in prostate cancer, dysregulated AR signaling mediated by DHT can support tumor growth, progression, and resistance to therapy.

The age-related stability of intraprostatic DHT levels highlights the importance of local androgen metabolism in prostate health and disease. Therapeutic interventions, such as 5α-reductase inhibitors (e.g., finasteride and dutasteride), have been developed to reduce DHT production and mitigate its effects on the prostate. These inhibitors have demonstrated efficacy in reducing prostate size in BPH and delaying disease progression in certain cases of prostate cancer[14, 15]. However, the complex interplay between systemic and local androgen regulation continues to be an area of active research, particularly in understanding how DHT-driven AR signaling contributes to prostate pathologies across different stages of life.

Estrogen and Its Interplay with Androgens Estrogen plays a significant role in the pathogenesis of benign prostatic hyperplasia (BPH), particularly due to its dual receptor-mediated effects on prostate tissue. The prostate expresses two main types of estrogen receptors: estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ), which are distributed in both stromal and epithelial cells of the prostate. These receptors mediate contrasting effects, contributing to the complexity of estrogen's influence on prostate physiology and pathology[16–18].

ERα and ERβ: Contrasting Roles in Prostate Tissue: ERα activation is predominantly linked to pro-proliferative, pro-inflammatory, and fibrogenic effects. Its stimulation promotes stromal cell proliferation and extracellular matrix production, contributing to the fibromuscular hyperplasia that characterizes BPH. Additionally, ERα signaling is associated with increased expression of inflammatory cytokines and growth factors, exacerbating stromal proliferation and inflammatory microenvironment in the prostate. Conversely, ERβ activation is generally protective and anti-proliferative. It counteracts the effects of ERα by suppressing inflammation, inhibiting epithelial cell proliferation, and promoting apoptosis, thereby maintaining tissue homeostasis[19–21].

Hormonal Imbalance and Its Role in BPH Progression: Aging is accompanied by a relative increase in the estrogen-to-androgen ratio, primarily due to declining testosterone levels while estrogen levels remain stable or even increase due to peripheral aromatization of androgens into estrogens. This hormonal imbalance leads to the preferential activation of ERα over ERβ. Elevated ERα signaling stimulates stromal proliferation and fibromuscular expansion, hallmark features of BPH[22]. Furthermore, estrogen-mediated changes in prostate tissue microenvironment may enhance the sensitivity of stromal cells to growth factors and inflammatory mediators, perpetuating a cycle of hyperplasia and tissue remodeling.

Clinical Implications and Therapeutic Opportunities: Understanding the differential roles of ERα and ERβ in BPH has opened avenues for targeted therapies. Selective estrogen receptor modulators (SERMs) or ERβ agonists hold potential as therapeutic agents to mitigate the pro-proliferative effects of ERα while enhancing the protective functions of ERβ. Such interventions could provide a more tailored approach to managing BPH, particularly in patients with significant hormonal imbalances[23]. Moreover, strategies to modulate the estrogen-to-androgen ratio through lifestyle or pharmacological interventions may also play a role in BPH prevention or progression. Estrogen, through its receptors, exerts complex and multifaceted effects on the prostate. The age-related hormonal shifts favoring ERα-mediated signaling are critical contributors to the pathophysiology of BPH, highlighting the importance of estrogen as a therapeutic target in managing this condition[24].

Prolactin and Prostate Pathophysiology Prolactin, traditionally recognized for its pivotal role in lactation, has emerged as a multifunctional hormone with significant effects on the prostate gland. Prolactin receptors (PRLR), widely expressed in prostate epithelial and stromal cells, mediate its actions by triggering downstream signaling cascades such as the JAK-STAT, PI3K-Akt, and MAPK pathways[25]. These pathways contribute to the regulation of cellular growth, differentiation, and survival. One of the critical mechanisms by which prolactin exerts its influence on the prostate is through the enhancement of androgen receptor (AR) sensitivity. Prolactin signaling synergizes with androgens, amplifying their effects on prostate tissue. This heightened

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

sensitivity can lead to increased expression of androgen-responsive genes, promoting stromal and epithelial proliferation[26]. Moreover, prolactin-induced activation of stromal cell proliferation directly contributes to the structural and functional changes characteristic of benign prostatic hyperplasia (BPH).

Clinical studies have shown a correlation between elevated serum prolactin levels and increased BPH severity. Prolactin may stimulate inflammation and fibrosis within the prostate, exacerbating disease progression. Additionally, prolactin may indirectly influence prostate growth by modulating the local immune response and promoting angiogenesis, both of which are implicated in the pathogenesis of BPH[27, 28]. These findings underscore the potential of prolactin as a therapeutic target. Modulating prolactin levels or blocking PRLR activity could provide new avenues for managing BPH, particularly in patients with elevated prolactin levels. Further research is needed to elucidate the precise molecular mechanisms of prolactin in prostate pathophysiology and to develop targeted interventions

Systemic Hormones and Metabolic Factors Recent studies have elucidated a multifaceted relationship between systemic metabolic hormones and benign prostatic hyperplasia (BPH) pathogenesis. Insulin, leptin, and adiponectin have emerged as critical mediators in this process, linking metabolic dysfunction to prostatic tissue growth and inflammation[29]. Hyperinsulinemia and elevated levels of insulin-like growth factors (IGFs) are particularly noteworthy, as they promote prostatic epithelial proliferation through activation of the IGF receptor (IGFR) signaling pathway. This signaling cascade not only stimulates cell division but also inhibits apoptosis, thereby contributing to tissue hyperplasia. Moreover, IGFs interact with androgen signaling, a key driver of prostate growth, creating a synergistic effect that exacerbates the condition.[30] Leptin, a hormone predominantly secreted by adipocytes, is increasingly recognized for its role in fostering a pro-inflammatory environment within the prostate. It activates key signaling pathways, such as the JAK/STAT and MAPK cascades, which enhance stromal cell proliferation and secretion of pro-inflammatory cytokines. These inflammatory mediators further contribute to stromal hyperplasia and create a positive feedback loop that perpetuates prostate enlargement. The relationship between leptin and BPH underscores the influence of obesity and metabolic syndrome, as increased adiposity correlates with elevated leptin levels and reduced sensitivity to its regulatory functions.

Adiponectin, in contrast, exhibits anti-inflammatory and anti-proliferative effects. However, in individuals with obesity or metabolic syndrome, adiponectin levels are often reduced, tipping the balance toward a pro-inflammatory and pro-proliferative state. This imbalance highlights the importance of systemic metabolic changes in shaping the local prostatic microenvironment[31, 32]. Collectively, these findings underscore the complex interplay between metabolic alterations, hormonal dysregulation, and localized prostate growth. Understanding these mechanisms offers potential therapeutic avenues, such as targeting IGF signaling, modulating leptin activity, or restoring adiponectin levels, to mitigate BPH progression, particularly in patients with coexisting metabolic disorders.

Therapeutic Implications Understanding the hormonal basis of benign prostatic hyperplasia (BPH) has significantly advanced the development of pharmacological therapies aimed at modulating androgenic and estrogenic pathways. A critical target in these therapeutic strategies is dihydrotestosterone (DHT), a potent androgen that plays a key role in prostate enlargement. 5α-reductase inhibitors, such as finasteride and dutasteride, effectively inhibit the conversion of testosterone to DHT, thereby reducing DHT levels within the prostate. This reduction not only mitigates the progression of prostate enlargement but also alleviates associated lower urinary tract symptoms (LUTS) commonly seen in BPH patients.

In addition to targeting androgen pathways, selective estrogen receptor modulators (SERMs) are being explored for their potential to regulate estrogen-mediated effects in the prostate. By selectively modulating estrogen receptor activity, SERMs may help balance the hormonal environment and reduce prostatic tissue proliferation. Similarly, therapies targeting prolactin, a hormone implicated in prostate growth and inflammation, are under investigation. Anti-prolactin agents aim to suppress excessive prolactin signaling, which may contribute to the pathological changes seen in BPH. Together, these advancements highlight a multifaceted approach to hormonal modulation as a promising avenue for improving BPH management and patient outcomes.

Future Directions

Despite advances in understanding hormonal influences on BPH, significant gaps remain. Future research should focus on:

a. Elucidating the molecular mechanisms underpinning androgen and estrogen receptor signaling.
b. Investigating the role of systemic metabolic hormones in prostate stromal-epithelial interactions.
c. Developing novel hormonal therapies with improved efficacy and safety profiles.

CONCLUSION

Hormonal changes, particularly involving androgens, estrogens, and prolactin, play a pivotal role in the development and progression of BPH. The interplay between systemic and localized hormonal factors underscores the complexity of BPH pathogenesis. Advances in hormonal therapies offer promising avenues for improving patient outcomes and quality of life. A deeper understanding of the hormonal milieu in BPH will pave the way for innovative therapeutic strategies.

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

REFERENCES

1. Ajayi, A., Abraham, K.: Understanding the role of estrogen in the development of benign prostatic hyperplasia. African Journal of Urology. 24, 93–97 (2018). https://doi.org/10.1016/j.afju.2018.01.005
2. Bortnick, E., Brown, C., Simma-Chiang, V., Kaplan, S.A.: Modern best practice in the management of benign prostatic hyperplasia in the elderly. Therapeutic Advances in Urology. 12, 1756287220929486 (2020). https://doi.org/10.1177/1756287220929486
3. Cao, D., Sun, R., Peng, L., Li, J., Huang, Y., Chen, Z., Chen, B., Li, J., Ai, J., Yang, L., Liu, L., Wei, Q.: Immune Cell Proinflammatory Microenvironment and Androgen-Related Metabolic Regulation During Benign Prostatic Hyperplasia in Aging. Front. Immunol. 13, (2022). https://doi.org/10.3389/fimmu.2022.842008
4. Chen, B., Cao, D., Chen, Z., Huang, Y., Lin, T., Ai, J., Liu, L., Wei, Q.: Estrogen regulates the proliferation and inflammatory expression of primary stromal cell in benign prostatic hyperplasia. Translational Andrology and Urology. 9, 32231–32331 (2020). https://doi.org/10.21037/tau.2020.02.08
5. Ibiam, U.A., Uti, D.E., Ejeogo, C.C., Orji, O.U., Aja, P.M., Nwamaka, E.N., Alum, E.U., Chukwu, C., Aloke, C., Itodo, M.O., Agada, S.A., Umoru, G.U., Obeten, U.N., Nwobodo, V.O.G., Nwadum, S.K., Udoudoh, M.P.: Xylopia aethiopica Attenuates Oxidative Stress and Hepatorenal Damage in Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. Journal of Health and Allied Sciences NU. 14, 477–485 (2024). https://doi.org/10.1055/s-0043-1777836
6. Ibiam, U.A., Uti, D.E., Ejeogo, C.C., Orji, O.U., Aja, P.M., Nwamaka, E.N., Alum, E.U., Chukwu, C., Aloke, C., Chinedum, K.E., Agu, P., Nwobodo, V.: In Vivo and in Silico Assessment of Ameliorative Effects of Xylopia aethiopica on Testosterone Propionate-Induced Benign Prostatic Hyperplasia. Pharmaceutical Fronts. 05, e64–e76 (2023). https://doi.org/10.1055/s-0043-1768477
7. Nicholson, T.M., Ricke, W.A.: Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation. 82, 184–199 (2011). https://doi.org/10.1016/j.diff.2011.04.006
8. Fu, X., Wang, Y., Lu, Y., Liu, J., Li, H.: Association between metabolic syndrome and benign prostatic hyperplasia: The underlying molecular connection. Life Sciences. 358, 123192 (2024). https://doi.org/10.1016/j.lfs.2024.123192
9. Xu, G., Dai, G., Huang, Z., Guan, Q., Du, C., Xu, X.: The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy. RRU. 16, 205–214 (2024). https://doi.org/10.2147/RRU.S477396
10. Cannarella, R., Condorelli, R.A., Barbagallo, F., La Vignera, S., Calogero, A.E.: Endocrinology of the Aging Prostate: Current Concepts. Front. Endocrinol. 12, (2021). https://doi.org/10.3389/fendo.2021.554078
11. Hata, J., Harigane, Y., Matsuoka, K., Akaihata, H., Yaginuma, K., Meguro, S., Hoshi, S., Sato, Y., Ogawa, S., Uemura, M., Kojima, Y.: Mechanism of Androgen-Independent Stromal Proliferation in Benign Prostatic Hyperplasia. International Journal of Molecular Sciences. 24, 11634 (2023). https://doi.org/10.3390/ijms241411634
12. Naamneh Elzenaty, R., du Toit, T., Flück, C.E.: Basics of androgen synthesis and action. Best Practice & Research Clinical Endocrinology & Metabolism. 36, 101665 (2022). https://doi.org/10.1016/j.beem.2022.101665
13. Foley, C., Mitsiades, N.: Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. HORM CANC. 7, 84–103 (2016). https://doi.org/10.1007/s12672-015-0239-9
14. Thirumalai, A., Cooper, L.A., Rubinow, K.B., Amory, J.K., Lin, D.W., Wright, J.L., Marck, B.T., Matsumoto, A.M., Page, S.T.: Stable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone. J Clin Endocrinol Metab. 101, 2937–2944 (2016). https://doi.org/10.1210/jc.2016-1483
15. Goldenberg, L., So, A., Fleshner, N., Rendon, R., Drachenberg, D., Elhilali, M.: The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme? Can Urol Assoc J. 3, S109–S114 (2009)
16. Chen, B., Cao, D., Chen, Z., Huang, Y., Lin, T., Ai, J., Liu, L., Wei, Q.: Estrogen regulates the proliferation and inflammatory expression of primary stromal cell in benign prostatic hyperplasia. Translational Andrology and Urology. 9, 32231–32331 (2020). https://doi.org/10.21037/tau.2020.02.08
17. Vickman, R.E., Franco, O.E., Moline, D.C., Vander Griend, D.J., Thumbikat, P., Hayward, S.W.: The role of the androgen receptor in prostate development and benign prostatic hyperplasia: A review. Asian Journal of Urology. 7, 191–202 (2020). https://doi.org/10.1016/j.ajur.2019.10.003
18. Da Silva, M.H.A., De Souza, D.B.: Current evidence for the involvement of sex steroid receptors and sex hormones in benign prostatic hyperplasia. Research and Reports in Urology. 11, 1–8 (2019). https://doi.org/10.2147/RRU.S155609
19. Christoforou, P., Christopoulos, P.F., Koutsilieris, M.: The Role of Estrogen Receptor β in Prostate Cancer. Mol Med. 20, 427–434 (2014). https://doi.org/10.2119/molmed.2014.00105

OPEN ACCESS
ONLINE ISSN: 2992-5479
PRINT ISSN: 2992-605X

20. Cannarella, R., Condorelli, R.A., Barbagallo, F., La Vignera, S., Calogero, A.E.: Endocrinology of the Aging Prostate: Current Concepts. Front. Endocrinol. 12, (2021). https://doi.org/10.3389/fendo.2021.554078
21. Liu, J., Zhang, J., Fu, X., Yang, S., Li, Y., Liu, J., DiSanto, M.E., Chen, P., Zhang, X.: The Emerging Role of Cell Adhesion Molecules on Benign Prostatic Hyperplasia. International Journal of Molecular Sciences. 24, 2870 (2023). https://doi.org/10.3390/ijms24032870
22. Horstman, A.M., Dillon, E.L., Urban, R.J., Sheffield-Moore, M.: The Role of Androgens and Estrogens on Healthy Aging and Longevity. J Gerontol A Biol Sci Med Sci. 67, 1140–1152 (2012). https://doi.org/10.1093/gerona/gls068
23. Nicholson, T.M., Moses, M.A., Uchtmann, K.S., Keil, K.P., Bjorling, D.E., Vezina, C.M., Wood, R.W., Ricke, W.A.: Estrogen receptor-alpha is a key mediator and therapeutic target for bladder complications of benign prostatic hyperplasia. J Urol. 193, 722–729 (2015). https://doi.org/10.1016/j.juro.2014.08.093
24. Figueira, M.I., Carvalho, T.M.A., Macário-Monteiro, J., Cardoso, H.J., Correia, S., Vaz, C.V., Duarte, A.P., Socorro, S.: The Pros and Cons of Estrogens in Prostate Cancer: An Update with a Focus on Phytoestrogens. Biomedicines. 12, 1636 (2024). https://doi.org/10.3390/biomedicines12081636
25. Al-Chalabi, M., Bass, A.N., Alsalman, I.: Physiology, Prolactin. In: StatPearls. StatPearls Publishing, Treasure Island (FL) (2025)
26. Szukiewicz, D.: Current Insights in Prolactin Signaling and Ovulatory Function. International Journal of Molecular Sciences. 25, 1976 (2024). https://doi.org/10.3390/ijms25041976
27. Adejumo, B.I.G., Williams, O.L., Odigie, E.B., Unachukwu, I.G., Abdulrahman, O.N., Dimkpa, U., Uzor, S., Adebowale, O.M., Oke, O.M.: Serum Levels of Reproductive Hormones and Their Relationship with Age in Men with Benign Prostatic Hyperplasia in Benin City, Edo State. Health. 12, 1121–1131 (2020). https://doi.org/10.4236/health.2020.129082
28. Auriemma, R.S., Del Vecchio, G., Scairati, R., Pirchio, R., Liccardi, A., Verde, N., de Angelis, C., Menafra, D., Pivonello, C., Conforti, A., Alviggi, C., Pivonello, R., Colao, A.: The Interplay Between Prolactin and Reproductive System: Focus on Uterine Pathophysiology. Front. Endocrinol. 11, (2020). https://doi.org/10.3389/fendo.2020.594370
29. Wang, X., Yu, Q., Michel, M.C.: Editorial: Benign prostatic hyperplasia and overactive bladder: new members of metabolic syndrome. Front. Urol. 3, (2023). https://doi.org/10.3389/fruro.2023.1272592
30. Abdollah, F., Briganti, A., Suardi, N., Castiglione, F., Gallina, A., Capitanio, U., Montorsi, F.: Metabolic Syndrome and Benign Prostatic Hyperplasia: Evidence of a Potential Relationship, Hypothesized Etiology, and Prevention. Korean J Urol. 52, 507–516 (2011). https://doi.org/10.4111/kju.2011.52.8.507
31. Choi, H.M., Doss, H.M., Kim, K.S.: Multifaceted Physiological Roles of Adiponectin in Inflammation and Diseases. International Journal of Molecular Sciences. 21, 1219 (2020). https://doi.org/10.3390/ijms21041219
32. Clemente-Suárez, V.J., Redondo-Flórez, L., Beltrán-Velasco, A.I., Martín-Rodríguez, A., Martínez-Guardado, I., Navarro-Jiménez, E., Laborde-Cárdenas, C.C., Tornero-Aguilera, J.F.: The Role of Adipokines in Health and Disease. Biomedicines. 11, 1290 (2023). https://doi.org/10.3390/biomedicines11051290

CITE AS: Bwanbale Geoffrey David. (2025). The Role of Hormonal Changes in the Development of Benign Prostatic Hyperplasia: A Mini Review. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY, 6(1):141-145. https://doi.org/10.59298/NIJPP/2025/61141145